2015 Fast Congress Banner
2015 Fast Congress Banner

Phenotypic Drug Discovery

Phenotypic screening (A.K.A. classical pharmacology) has been historically used in drug discovery. While technological developments have made the prevalence of target-based screening more popular, statistical analysis shows that a disproportionate number of first-in-class drugs with novel mechanisms of action come from phenotypic screening. Cambridge Healthtech Institute’s 3rd Annual Phenotypic Drug Discovery meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models, and subsequent target identification and validation.

Day 1 | Day 2 | Short CoursesDownload Brochure

Sunday, November 8

5:00 pm Short Course Registration and Main Conference Pre-Registration

6:00-9:00 (SC1) Dinner Short Course*: Introduction to High-Content Phenotypic Screening

*Separate registration required.

Monday, November 9

7:00 am Conference Registration and Morning Coffee

Organoids and Primary Organotypic 3D Culture in Drug Discovery

8:00 Chairperson’s Opening Remarks

David Grainger, Ph.D., Distinguished Professor, Pharmaceutical Chemistry, University of Utah

8:10 Characterizing Organotypic Tumor Tissue Slice Culture for Use in Drug Discovery

Emma Davies, Ph.D., Senior Scientist, Oncology iMed, AstraZeneca

Preclinical in vitro models that better represent the complexity of an in situ human tumor are being sought as part of the IMI project PREDECT (www.predect.eu). It is hoped that better recapitulation of the clinical situation, preclinically, will greatly improve target validation and ultimately get better drugs to patients. As part of PREDECT we have been investigating the use of organotypic slice culture for cultivation of tumor material ex vivo.

8:35 High-Throughput Screening Using a Primary Human 3D Organotypic Culture

Hilary Kenny, Ph.D., Research Associate (Assistant Professor), Obstetrics & Gynecology, University of Chicago

The tumor microenvironment contributes to cancer progression, metastasis and drug resistance. A multilayered culture containing primary human fibroblasts, mesothelial cells and extracellular matrix was adapted into a robust and reliable 384- and 1,536-multi-well high-throughput screening assay that reproduces the human ovarian cancer metastatic microenvironment. The identified inhibitors were validated using multiple cells and independent in vitro and in vivo secondary assays. These assays specifically investigated the effect of the compounds on ovarian cancer cell adhesion, invasion, proliferation and metastasis to the peritoneal microenvironment. Collectively, these findings show that a 3D organotypic culture can be adapted for high-throughput screening.

9:00 Analyses of Prostate and Bladder Tumor Organoids

Michael M. Shen, Ph.D., Professor, Medicine and Genetics and Development, Columbia University

9:25 A 3D Culture Model of Alzheimer’s Disease: Challenges and Perspectives

Doo Yeon Kim, Ph.D., Assistant Professor, Neurology, Genetics and Aging Research Unit, Massachusetts General Hospital, Harvard Medical School

We recently developed a human neural cell culture model of Alzheimer’s disease (AD) based on a three-dimensional (3D) cell culture system. This unique cellular AD model recapitulated key events of the pathogenic cascade of this disease, including β-amyloid plaques and neurofibrillary tangles. In this talk, I will present recent updates on our 3D culture model and discuss challenges and prospects.

9:50 Sponsored Presentation (Opportunity Available)

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 3D Brain Models to Study Neurotoxicity and Neurodegeneration

Lena Smirnova, Ph.D., Research Associate, Johns Hopkins Center for Alternatives to Animal Testing, Johns Hopkins University Bloomberg School of Public Health

The increasing incidence of neurodevelopmental disorders and lack of cure for neurodegenerative diseases such as Parkinson’s require new human-relevant models. iPSCs allow addressing gene-environment interactions. Therefore, we developed two 3D human neuronal models: (1) human iPSC-derived 3D mini-brains to recapitulate neurodevelopment and after maturation to selectively damage dopaminergic neurons by Parkinson agents, and (2) a homogeneous LUHMES 3D dopaminergic neuronal model, to study their molecular signatures and pathways.

11:15 In vitro Hydrogel-Based Culture of Patient-Derived Xenografts for Cancer Studies

Daniel A. Harrington, Ph.D., Assistant Director, Collaborative Research Laboratory; Faculty Fellow, BioSciences, Rice University

Many primary cell types, including PDX models, are not readily grown on conventional 2D tissue culture substrates. We describe our ongoing efforts using customizable, biocompatible hydrogels to enable the extended laboratory culture of cancer PDXs and other primary cells in 3D. This platform permits the use of these desirable cell lines for laboratory manipulation and drug testing in miniaturizable formats.

11:40 Addressing Challenges in Organoid Culture Using a High-Throughput Microraft Array Platform

Adam D. Gracz, Ph.D., Postdoctoral Fellow, Magness Lab, Gastroenterology and Hepatology, University of North Carolina, Chapel Hill

Organoid cultures have emerged as a powerful tool for understanding adult stem cell biology in a wide range of tissues. However, conventional organoid methodology presents unique challenges in terms of accurate quantification and retrieval of samples. Bioengineered microraft arrays address these challenges by providing a high-throughput platform for long-term clonal tracking and retrieval of organoids. As proof of concept, we use microraft arrays to study stem cell-niche interaction and probe the molecular characteristics of organoid phenotypes.

12:05 pm Comparing 2D Kidney Cell and 3D Kidney Organoid Cultures for in vitro Drug Toxicity Assays

David Grainger, Ph.D., Distinguished Professor, Pharmaceutical Chemistry, University of Utah

Many new 3-D cell culture models seek to preserve in vivo-like organization within tissue-like or organoid constructs to elicit more relevant pharmacological toxicity and toxicity marker up-regulation. We report our development of a kidney proximal tubule (PT) 3D gel-based organoid culture comparison against conventional 2D kidney cell cultures to assess nephrotoxicity markers from common model drugs and select nanoparticles.

12:30 Luncheon Presentation: Profiling of 1,600 Novel Natural Product-Based Compounds across 13 Human Primary Cell-Based Phenotypic Assays

Jamil Aarbiou, Ph.D., Team Leader, Target Discovery and Validation, Biology, BioFocus, a Charles River Company

To support our partners’ drug discovery programs, we developed >100 phenotypic human primary cell assays. One of our clients, Janssen Incubator, developed a natural product drug discovery platform using natural product scaffold-based chemical entities. We used 13 human primary cell-based assays, from RA, IPF, T2D or healthy donors, to screen 1,600 compounds. Data from these screens provided valuable starting points for further compound optimization and highlighted which assays could help identify unique, disease-relevant mechanisms of action.

Phenotypic Screening for New Target, Pathway and Mechanism-of-Action Discovery

2:00 Chairperson’s Remarks

David C. Swinney, Ph.D., CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3)

2:05 Phenotypic Screening Identifies New, Diverse Molecular Mechanisms of Action (MMOAs)

David C. Swinney, Ph.D., CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3)

There is a great need for new medicines with novel mechanisms that provide increased efficacy and improved safety. Recently approved medicines work in many different ways and phenotypic assays contributed to the identification of the many, different MMOAs. It is clear that phenotypic assays are an important tool to identify novel MMOAs and the corresponding medicines.

2:30 Small-Molecule Discovery for Diabetes: The Importance of Combining a Phenotypic Approach and Mechanism-of-Action Studies

Bridget Wagner, Ph.D., Director, Pancreatic Cell Biology and Metabolic Disease, CSofT, Broad Institute of MIT and Harvard

Identifying small molecules that impact on pancreatic beta-cell survival and function could have a great impact on developing new diabetes therapies. Taking a phenotypic cell-based approach can help speed this process. However, a major bottleneck in the process is determining the mechanism of action of novel compounds. Here, I will discuss our approaches to small-molecule discovery in the beta cell, as well as current efforts to streamline the process of understanding mechanistic activity.

2:55 Targeting Tumor Recurrence through Physiologically Relevant Screens

Kimberly Hartwell, Ph.D., Research Scientist, Vertex Pharmaceuticals

Efforts to develop more effective cancer therapies may benefit from high-throughput screening systems that reflect the complex physiology of the disease, including cancer stem cells and supportive interactions with the malignant microenvironment. Primary cancer cells were cultured with stromal cells, as were primary normal cells, revealing cancer-specific stem-cell dependencies by small-molecule screening.

MaxCyte3:20 Presentation to be Announced

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Information in Biological Images: Targeting Diseases and Characterizing Compounds

Anne E. Carpenter, Ph.D., Director, Imaging Platform, Broad Institute of Harvard and MIT

Microscopy images contain rich information about the state of cells, tissues and organisms. Our laboratory extracts patterns of morphological perturbations (“signatures”) from images to identify similarities and differences between chemical or genetic treatments, with the ultimate goal to identify the causes and potential cures of disease. Using model systems that are more and more physiologically relevant, we are developing assays and accompanying algorithms to extract multi-parametric morphological fingerprints of cell populations.

5:10 Target Hypothesis Generation and Validation for PTS Hits Using Target Space Annotations

Andras Bauer, Ph.D., Senior Scientist, Immunology and Respiratory Therapeutic Area, Boehringer Ingelheim

Binding of a small molecule to its target domain is a prerequisite of biological activity. By interrogating existing target-ligand pairs covering the known ligandable proteome, we can predict candidate target-ligand pairs for phenotypic screening hits. An alternative to this method is using purified protein libraries representing ligandable domains to screen for protein-target domain interactions in a label-free format. This talk will focus on implementation of both technologies for generating and validating target-ligand hypotheses for bioactive compounds emerging from phenotypic screens.

5:35 Repurposing Drug Screens to Elucidate New Drug Targets and Pathways for Infectious Disease and Cancer

Wei Sun, Ph.D., Scientist, Therapeutics for Rare and Neglected Diseases (TRND), National Center for Advancing Translational Sciences (NCATS)

NCATS has established a unique approved drug collection containing 4,265 compounds. Using this library, we have screened against several disease models, including malaria gametocytes, antibiotic-resistant bacteria and drug-resistant ovarian cancer. Compared to target-based screens, these phenotypic-based screens are more disease relevant, offering additional biological complexity. Not only were potent candidates for further drug development identified, but these screens also revealed novel molecular targets and pathways that increased insight into these disease processes.

6:00-7:00 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 Short Course Registration

7:00-9:00 (SC2) Dinner Short Course*: Screening Strategies for Cancer Immunotherapy

*Separate registration required.

Day 1 | Day 2 | Short Courses | Download Brochure

Tuesday, November 10

7:00 am Conference Registration and Morning Coffee

Phenotypic Screening Using Primary and Stem Cell-Derived Models

8:00 Chairperson’s Opening Remarks

Jing Li, Ph.D., Director, Genomics and Phenotypic Screening, Merck Research Laboratories

8:10 Phenotypic Discovery Approaches to Generative Medicine in AstraZeneca

Per Erik Stromstedt, Ph.D., Director, Screening Sciences & Sample Management/Reagent & Assay Development, AstraZeneca R&D

Native cell types with relevance to drug discovery in cardiac regeneration and islet health are being used by AstraZeneca to develop assays with improved physiological relevance over traditional approaches. Development and application of phenotypic assays using cellular systems utilizing the iPS technology, precise genome editing (PGE) technologies and primary human cells will be discussed. The presentation will use case studies to demonstrate both the advantages and hurdles of these approaches to identify novel targets, pathways or mode of action.

8:35 Opportunities and Challenges with Phenotypic Screening Using Human iPS-Derived Neurons

Hicham Alaoui, Ph.D., Director, Biochemical and Cellular Pharmacology, Genentech

9:00 Utilizing hiPSC-Derived Differentiated Cells for High-Throughput Drug Screening

Anne Bang, Ph.D., Director, Cell-Based Disease Modeling and Screening, Sanford-Burnham-Prebys Medical Discovery Institute

Development of technology platforms that can be used to perform compound screens against patient-specific human induced pluripotent stem cell (hiPSC)-derived cell types with relatively high throughput will be essential to realize the potential that these cells hold for disease modeling and drug discovery. Towards this goal, we have been working to develop a standardized battery of assays against which hiPSC-derived neurons can be screened for specific phenotypes. Our results demonstrate the feasibility of performing higher throughput drug screens on hiPSC-derived neurons and establish platforms for future screens using patient specific cells.

9:25 Sponsored Presentation (Opportunity Available)

9:55 Coffee Break in the Exhibit Hall with Poster Viewing

Case Studies in Phenotypic Drug Discovery

10:45 Lessons Learned in Phenotypic Drug Discovery

Fabien Vincent, Ph.D., Associate Research Fellow, Hit Discovery and Lead Profiling, Pfizer

This presentation will cover a collection of scientific vignettes (i.e., lessons) based on in-house experience with phenotypic drug discovery and touching on a broad range of topics including designing the best phenotypic assays, primary cells and donor-to-donor variability analysis, hit triage and validation, use and misuse of chemogenomics libraries, toxicity and safety derisking of PDD hits.

11:10 Identification of HIV Latency Reactivation Agents through Phenotypic Screening: A Case Study

David Tellers, Ph.D., Principal Scientist, Discovery Chemistry, Merck

Recent advances in the fields of biology, chemistry, proteomics and screening technology have greatly improved our chances of identifying underlying protein targets. We will highlight progress on all these fronts as they relate to the discovery of mechanisms and chemical matter, derived from an ultra-high throughput phenotypic screen, which induces latent HIV expression in infected cells.

11:35 A Case Study of Applying Annotated Chemical Libraries and Chemical Biology Strategy in Phenotypic Screens

Zining Wu, Ph.D., Investigator, Molecular Discovery Research, GlaxoSmithKline

Sickle cell disease (SCD) is one of the most common genetic diseases and a major source of morbidity and mortality worldwide. Increasing fetal hemoglobin (HbF) has long been a therapeutic goal in management of SCD. This presentation will cover the strategy and outcome of phenotypic screens for HbF inducers. I will discuss the importance of setting up physiologically relevant cellular models in hit identification, the challenges and learnings from screens using primary human cells and high-content data handling and analysis. The value of using annotated chemical libraries in phenotypic screening and the discovery of novel chemical modulators will also be presented.

12:00 pm Phenotypic Screening for Anti-Diabetes Agents

Francis Willard, Ph.D., Senior Research Scientist, Quantitative Biology, Lilly Research Labs

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:10 Close of Conference

Day 1 | Day 2Short Courses | Download Brochure

For questions about the meeting, please contact: 
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute (CHI)
E-mail: juliab@healthtech.com

For sponsorship and exhibit sales information, please contact:
Katelin Fitzgerald
Senior Business Development Manager
Cambridge Healthtech Institute (CHI)
Phone: (+1) 781-972-5458
Email: kfitzgerald@healthtech.com 

For media and association partnerships, please contact:
Jaime Hodges
Marketing Manager
Cambridge Healthtech Institute (CHI)
Phone (+1) 781-972-5429
Email: jhodges@healhtech.com